Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced Arjun Ishwar has joined the company as vice president of sales and marketing.
Arjun Ishwar brings extensive experience in corporate strategic planning and execution, sales and marketing leadership, and commercialization combined with a technical background in tissue engineering and regenerative medicine. At Miach, he will lead commercialization efforts for the BEAR Implant, which was launched in the U.S. in fall 2021. To date, more than 500 patients have been treated with the BEAR Implant in both commercial and clinical use.
“Arjun is a proven leader in the medical device field and has a strong track record of developing and implementing business strategies for medical technologies that improve patients’ lives. Lending his expertise to the BEAR Implant is a natural fit,” said Patrick McBrayer, president and CEO, Miach Orthopaedics. “Our experience working together to drive adoption of tissue regeneration products will be invaluable as we continue the commercial rollout of the BEAR Implant in the U.S.”
Arjun Ishwar has held various commercial leadership roles within the medical device industry. Prior to joining Miach, he served as chief commercial officer of MY01. Previously, he spent nearly 10 years in roles of increasing responsibility at ACell, a regenerative medicine company focused on the reconstruction of acute injuries, where in his last position as senior director and general manager he was responsible for overseeing the commercial and pipeline strategies for the wound management portfolio – the company’s largest and strongest growing franchise – as well as surgical markets. Earlier in his career, he served in multiple sales and marketing roles for Integra Lifesciences focused within its trauma and burn reconstruction business. He earned his Bachelor and Master of Science degrees in biomedical engineering from Purdue University.
Ishway said,
“My career has been focused on leading commercial teams bringing cutting edge medical technologies to patients, and I’m excited to further this passion at Miach. The BEAR Implant helps patients restore the normal anatomy of their knee and has the potential to become the new standard of care in the treatment of ACL tears. I look forward to driving the strategy that makes this possible.”
About The BEAR® Implant – The Bridge-Enhanced® ACL Restoration (BEAR®) Implant is a proprietary bio-engineered implant used to facilitate healing of the torn ACL. The BEAR Implant is the first medical technology to demonstrate, with Level 1 clinical evidence, that it enables the body to heal its own torn ACL. Unlike reconstruction, which is the current standard of care, the BEAR Implant does not require a second surgical wound site to remove a healthy tendon from another part of the leg or the use of a donor tendon. The BEAR Implant acts as a bridge between the two ends of the torn ACL. The surgeon injects a small amount of the patient’s own blood into the implant and inserts it between the torn ends of the ACL in a minimally invasive procedure. The combination of the BEAR Implant and the patient’s blood enables the body to heal the torn ends of the ACL back together while maintaining the ACL’s original attachments to the femur and tibia. The BEAR Implant is resorbed by the body as the ACL heals.
The BEAR Implant was granted De Novo Approval from the U.S. Food and Drug Administration in December 2020. It is indicated for skeletally mature patients at least 14 years of age with a complete rupture of the ACL, as confirmed by MRI. Patients must have an ACL stump attached to the tibia to facilitate the restoration. The BEAR device must be implanted within 50 days of injury. Visit miachortho.com for complete product information, including Instructions for Use.